Baseline patient features
high-density lipoprotein, T2DM, rectus femoris mass
DIABETIC PERIPHERAL NEUROPATHY
Totally 948 diabetics aged 54.35 ± 12.71 years were included and assigned to the DPN (n=234) and non-DPN (n=714) groups (Clinical characteristics of T2DM patients with DPN versus without DPN.Values were expressed as mean ± SD for normally distributed data and median with interquartile range for non-normally distributed data, or n (%). Differences among the groups were analyzed by ANOVA for normally distributed values and by the Kruskal–Wallis test for nonparametric values. Pearson’s χ2 test was employed to analyze categorical data. *p<0.05, **p<0.001. BMI, body max index; TG, triglycerides; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, glycated hemoglobin; RFMI, rectus femoris mass index.In addition, patients were categorized according to RFMI by interquartile range at the cut-off points of 1.96, 2.37 and 2.81 cm²/m². Patient features in various groups are shown in Clinical characteristics of T2DM patients stratified by RFMI categories.Values were expressed as mean ± SD for normally distributed data and median with interquartile range for non-normally distributed data, or n (%). Differences among the groups were analyzed by ANOVA for normally distributed values and by the Kruskal–Wallis test for nonparametric values. Pearson’s χ2 test was employed to analyze categorical data. *p<0.05, **p<0.001. BMI, body max index; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; Cr, serum creatinine; UA, serum uric acid; CysC, serum cystatin C; TG, triglycerides; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, glycated hemoglobin; UAER, urine albumin excretion rate; FCP, fasting c-peptide; DPN, diabetic peripheral neuropathy.